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Hete we report the cloning of the cDNA for human CD40-Ligand (CD4O-L) from a CD4positive T cell clone. The deduced amino acid sequence 
predicts a type II membrane protein of 261 amino acids. Northern blot and FACS analysis of PBMNC revealed that the human CD40-L can be 
detected on T cells and is absent from B cells and monocytes. The human CD40-L is expressed on both CD4- and CDS-positive T cells, (CD45RO’) 
and (CD45RA+) subsets. We observed that IL-4, an inducer of IgE production, upregulated CD40-L mRNA level while IFNy, an inhibitor of 
IgE synthesis, reduced the expression of CD40-L mRNA. These data suggest a the correlation between human 0-L expression and IgE 
production. 
CD@ ligand: Cloning; IFNy; IgE regulation; IL-J: T cell 
The CD40 moIecule is a glycoprotein expressed on 3 
lymphocytes, epithelial cells and some carcinoma cells 
(for review see [l]). Cross-linking of CD40 by anti- 
CD40 monoclonal antibodies mediates 3 cell prolifera- 
tion [2.3], adhesion [4]* survival [5] and differentiation 
t6-91. Recentfy, the murine cDNA for CD40-L has been 
cloned and was found to induce B cell proliferation as 
well as IgE production in the presence of IL-4 [lo]. In 
this report we describe the cloning of the human CD40- 
L cDNA from a CD4’ T cell clone library. The distribu- 
tion and expression of the human CD40-L mRNA and 
protein were studied using a specific cRNA probe and 
a CD40-Fc fusion protein. The expression of CD40-L 
was examined under conditions which induce switching 
to the E constant region and also IgE production. 
were raised by PHAIIL-2 stjmuiatiou of PBMNC according to the 
method of Yssel et al. I1 I]. The CD&positive T ceh clone, OU 50.1, 
is dog hair aliergen-specific T celI clone (Life et al., manuscript in 
preparation). The T cell lines HUT-78. MOLT-4; the B cell lines, 
RPM1 8226 and KM-9 the promyelomonocytic cell line, HL-GO; the 
histiocytic lymphoma cell line, U-937 and the monocytic cell line 
THP-1 were obtained from ATCC as was the BHK cell line. The 
Burkitt lymphoma cell line BL-2 was obtained from G. Lenoir (Lyon, 
France). RPMf 8866 and JY ~ymphoblastoid cell lines were obtained 
from K. fshizaka (La Jolla, CA) and J. de Vries (Palo Alto, CA), 
respectively. The Jurkat cell line was obtained from A. Bernard (Nice, 
France). The murine cell line EL-4 was a gift of R. Zubler (Geneva, 
Switzerland). Cell lines were cultured in RPM1 1640 supplemented 
with 2 mM glutamrne and 10% FCS. T cell clones were cultured in 
Yssel’s medium supplemented with 10% FCS. lonomycin and PMA 
were used at a final concentration of 1 PM and 10 n&ml, respectively. 
2.2. Reagents 
2, MATERIALS AND METHODS 
2.1. Celfs 
PBMNC were isolated by centrifugation over Ficoll-Hypaque and 
resuspended inYssel’s medium [I 1] supplemented with 10% foetal calf 
serum (FCS). The human CDCpositive T cell clones, JF7 and JF8 
Anti-CD40 mAb MCA 679 was purchased from Serotec Ltd (Ox- 
ford, UK). Control IgG, and IgM were obtained from Sigma (St. 
Louis, MO). IL-4 and IFNy were purchased from Amersham lntema- 
tional plc (Bucking~~msbj~, UK) and Genzyme (Boston, MA), re- 
spectively. The CD4O-IgG?, Fc fusion construct was a kind gift of L 
Stamenkovic (Eoston, MA) [12]. This was expressed in COS cells and 
purified as described [13]. Purified CD40-Fc was conjugated to FITC 
using the method of Titus et al. [14]. 
2.3. Detection of rhe human CDIO-Ligand usrng CD40-Fe 
Corr~s~~~e~~e aci&e.rs: J.-Y. Bonnefoy, Glaxo Institute for Motecu- 
lar Biology, 14 ch. des AuIx, 122s Plan les Ouates, Switzerland. Fax: 
(41) (22) 794 69 54. 
Abbrevrutions: CD40-L, CD40 l&and; PBMNC, peripheral blood 
mononuclear cells; PMA, phorbol my&tic acetate; PCR, polymerase 
chain reaction. 
The sequence of CD&t has been deposited in Genbank under ac- 
cession number L 07414. 
Cells (4 x 105 in 40 ,ul) were incubated with lo&ml purified FITC- 
conjugated r~mbinant CD40-Fc Fusion protein or with FITC-fgG>, 
(Becton Dickinson, Erembodegem, Belgium). For double stainmg, 
4 x 10’ cells were incubated with l@&ml FITC-conjugated CD40-Fe 
fusion protem and 10 @ml phycoerythrin (PE-) labelled monoclonal 
antibodies directed against lymphocyte sub populations. Anti-CD3 
(Leu 4a), -CD4 (Len3a+3b), -CDS (Leu-Za), -CD14 (Leu-M3), 
-CD20 (Leu-16). -CD16 (Leu-11) and CD57 (Len?) were obtained 
from Becton Dickinson. AntiCD45RO (IJCHLL) and anti-CD45 RA 
(2H41 were from Dako (Gtostrup. Denmark) and Coulter (Hialeah, 
FL), respectively. After 35 min of incubation at 4°C cells were washed 
in PBS containing 1% BSA and 2 mM NaN, and analysed on a 
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FACStar Plus flow cytometer (Becton Dickinson) equipped with an 
argon ion laser (Spectra Physics, Mountam View. CA) tuned at 488 
nm. A compensation etwork was used to eliminate the FITC emis- 
sion in the PE channel and the small contribution of PE in the FITC 
channel. Parameter settings were made using single labelled popula- 
tions. 
2.4. Cell sorting of leukocyte sub popubtions by flobr cytometq 
2 x 10s PBMNC were stained with optimal concentrations of FITC- 
or PE-labelled monoclonal antibodies directed agamst leukocyte sub 
populations. After cell sorting, an aliquot of each sorted population 
was re-analysed by flow cytometry and the purity of the cells was 
above 98%. 
2.5. Detection of the human CD40-Ligand mRNA with mouse CD40- 
Ligand cRNA probe 
Poly A+ RNA was isolated from EL-4 cells usmg the guanidium 
thi~y~ate~esium trifluoroa~~te (CsTFA) method [I 51 followed 
by oligo (dT)-cellulose chromatography [16]. cDNA was synthesised 
using a First-Strand cDNA synthesis kit (Pharmacia, Uppsala, Swe- 
den). The NindII-BumHI restriction fragment of the mouse CD40-L 
cDNA was amplified by polymerase chain reaction (PCR) [16] using 
the primers GGCGTTGACTCGAAGGCTCCCGATT and TGAG- 
GATCCTCAAATTGCAGCAACAC and was cloned m pBC KS* 
(Stratagene, La Jolla, CA), The insert was checked by DNA sequenc- 
ing [17]. The plasmid was linearized with BamHl and used as a tem- 
plate to synthesise a cRNA probe [IQ. For Northern blot assays. 
aliquots of RNA (2pg) purified by the guanidmm thiocyanate-CsTFA 
procedure were subjected to electrophoresis n 1% agarose, 6% fotmal- 
dehyde gels [16], electrotransferred tonylon’ membranes (Boehringer 
Mannheim, Mannheim, Germany), and fixed with UV irradiation 
1191. Hybridisation with cRNA probes was performed at 575°C fol- 
lowed by 4 washes m 4 x SSC. 1% SDS at 65°C and a treatment with 
ribonuclease A as described previously 1201. Membranes were stained 
with methylene blue to localise and quantify rRNA before hybridisa- 
tion [16]. 
2.6. Cloning of the human CD40-Ligand cDNA 
Poly A’ RNA was isolated from the JF7 CW’ human T cell clone 
using the guanjdium thio~anate-CsTFA procedure followed by two 
cycles of a&go (dT)-celluIose chromatography. cDNA was syn- 
thesised, linked to adapters and size selected using a Timesaver cDNA 
synthesis kit (Pharmacia) according to the manufacturers instructions. 
The cDNA was cloned in the EcoRI restriction site of 1gtlO and 
packaged using Gigapack II gold extract (Stratagene). One million of 
the 2.2 mullion plaque library (with more than 90% of phages contain- 
mg inserts) were screened using the mouse CD40-L ~jndII-~amH1 
restriction fragment labelled by random hexamer priming [16]. Hy- 
bridisation was carried out as described for Northern blot assays but 
with 15% formamide at 42°C and was followed by washes in 2 x SSC, 
1% SDS at 55°C. Ten independent AgtlO clones were isolated by 
multiple screening cycles. Seven clones contained inserts which could 
be amplified by PCR using ilgtl0 specific primers. The inserts were 
recloned from purified AgtlO DNA into pBluescript II SK (Strata~ne) 
and character&d by restriction mapping and sequencing of the insert 
ends 1161. The two EcoRI restrictron sub fragments of clone 6 were 
recloned in Ml3 mp18 and mp19. The DNA sequence was determined 
on both strands by the dideoxynucleotide chain termination method 
1171. 
2.7. Trunsfection of the human CD4@L rtlNA in BHK cells 
The 1.1 kb EcoRI restriction fragment of agtl0 clone 6 containing 
the open reading frame was recloned in pCDM8 [21]. Constructs with 
inserts in the two possible orientations were transfected into BHK cells 
by electroporation. Transfectants were analysed after 48 h of culture. 
2.8. Detection of the human CD40-Ligand mRNA wrth human CD40- 
ligand cRNA probe 
The 1.1 kb EcoRI restriction fragment of;lgt 10 clone 6 was reckoned 
260 
m pBluescript II SK. This plasmid, digested with the restriction en- 
zyme Hind111 was transcribed with T3 polymerase [IS]. The human 
CMO-L cRNA probe was then used to detect he CMO-L mRNA by 
Northern blot assay using the hybridisation and washing conditions 
described in detail elsewhere [ZO]. Control Northern blot assays for 
actin mRNA were performed in parallel using a BamHI restriction 
fragment of pHFyA1 [22] labelled by random hexamer priming as 
described [23]. 
2.9. Inductron of CD40-Ligand and IgE synthesa by IL-4 in PBMXC 
Cells were incubated at l&‘ml for 14 days in Iscove’s medium 
enriched with transferrm, bovine insulin, oleic acid, linoleic acid, 
palmitic acid, BSA (all from Sigma) and 10% FCS as described by 
Claassen et al. [24] in the presence of 200 U/ml recombmant IL-4. 
When added, IFNy and anti-CD40 mAb were used at 500 U/ml and 
I pg/ml, respectively. Ig productions were measured by specific ELISA 
as previously described [25]. Control cultures for the evaluation of 
preformed Ig were set up in the presence of cycloheximide (l~~~ml, 
Sigma). 
3. RESULTS 
3.1. Cloning of human CD46Ligand cDNA 
A cRNA probe complementary to a ~~~dII-~arn~I 
restriction fragment of the murine CD40-L cDNA was 
used to detect the corresponding human mRNA using 
a Northern blot assay (Fig. 1A). This probe gave, as 
expected, a clear signal with RNA isolated from the 
murine EL-4 cell line. Reducing the hybridisation strin- 
gency led to the appearance of a band with an identical 
molecular weight in RNA isolated from the human 
CD4’ clone JF7 which had been stimulated for 2 or 20 
hours with ionomycin and PMA (Fig. IA). No signal 
was detected in RNA isolated from unstimulated JF7 
cells by cross hybridisation with the mouse cRNA 
probe. A molecule binding to the human CD40-Fc fu- 
sion protein was detected by FACS analysis on the 
surface of activated JF7 cells (Fig. 1B). RNA isolated 
from JF7 cells stimulated for 2 hours with ionomycin 
and PMA was therefore used to clone the human CD40- 
L cDNA. Poiy A’ RNA isolated from these cells (Fig. 
1A) was subjected to reverse transcription and cloned 
in ,Xgt 10. One million plaques of the unamplified library 
were screened with the radio labelled BarnHI-Hind11 
mouse CD40-L cDNA restriction fragment using hy- 
bridisation conditions deduced from the Northern blot 
assay (Fig. 1). 0.5-l% of the plaques gave a positive 
signal on both replica membranes ubjected to the hy- 
bridisation, indicating that human CD40 mRNA repre- 
sented a fairly abundant mRNA in stimulated JF7 cells. 
Ten independent Agt 10 clones were isolated by multiple 
rounds of screening. Seven clones contained an insert 
which could be amplified by poIymerase chain reaction 
(PCR) using /2gtlO primers. Four clones were identical 
except for minor variations in the 5’ and 3’ ends, accord- 
ing to restriction mapping and sequencing. The DNA 
sequence of one of these inserts is represented in Fig. 2. 
Two inserts represented truncated cDNAs and the third 
comprised a CD40-L cDNA artefactually linked to an- 
other cDNA. 
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Fig. 1. Expression of human CD40-L mRNA (A) and surface protein (B) by JF’? cloned CDC T cell clone as detected by cross-hybridisation using 
a mouse CD40-L cRNA probe and FITC-labelled CD40-Fc fusion protein, respectively. Northern blot assays were performed using 2 pug 
unfractionated or 0.3 fig poly A+ RNA isolated from the human JF7 CD4’ T cell clone or murine EL-4 cells unstimulated (-) or stimulated (+) 
for the times indicated with ionomycin (1 ,uM) and PMA (10 &ml). Decreasing concentrations of formamide (50%, 40%,30%) were used to obtain 
cross-hybridisation between the murine cRNA probe and the RNA isolated from the human T cells. Autoradiography exposure time: 20 h. 
Conditions for the flow cytomet~ analysis of CD40-Fc or IgCk,, binding as described m section 2. 
3.2. Human CDIO-L&and sequence 
Sequencing of the iZgtl0 clone 6 revealed a 1.8 kb 
mRNA containing an open reading frame coding for 
261 amino acids highly homologous to the mouse 
CD40-L cDNA coding region (77.4%; Fig. 3). The de- 
duced amino acid sequence ncodes for 13 amino-termi- 
nal amino acids, followed by a 32-amino acid stretch of 
hydrophobic residues which could represent he signal/ 
anchor domain (Fig. 2). The protein contained two (one 
extracytoplasmic) potential glycosylation sites (Fig. 2). 
As shown for the mouse CD40-L [lo], the putative 
transmembrane segment deduced from the hydrophobi- 
city plot is followed by a potential protease cleavage 
site. The human CD40-L has five cysteines, compared 
to four for the murine CD40-L [IO]. 
The human CD40-L shares homology with TNFcx 
(23.4%) and TNFB (20.7%) which has led to a predicted 
compact trimer structure (Peitsch, M.C. and Jongeneel, 
V.C., personal communication). The 3’ non-coding re- 
gion of the CD40-L mRNA contains AUUU repeats 
which have been shown to confer instability to mRNA 
[26] as well as a long stretch of 33 CA repeats. 
To show that the cloned cDNA was encoding for a 
protein able to bind CD40, BHK cells were transfected 
with a 1.1 kb EcoRI restriction sub fragment of clone 
6 recloned in the pCDM8 expression vector in either 
sense or anti-sense orientation. Molecules binding to the 
human CD40-Fc fusion protein could clearly be de- 
tected at the surface of BHK cells transfected with the 
sense construct (Fig. 4). 
tein 
A radio labelled cRNA complementary to the EcoRI- 
Hind111 fragment of human CDQO-L cDNA was used 
to probe for the corresponding mRNA in human cell 
lines of various origins. Cells were probed either unstim- 
ulated or after 4 hours stimulation with ionomycin and 
PMA. Among the T cell lines HUT-78, MOLT-4 and 
Jurkat, B cell lines RPM1 8226, 8866, JY, BL-2 and 
IM-9 ; the histiocytic lymphoma cell line U-937 and the 
monocytic cell line THP-1, we detected the CD40-L 
mRNA only in Jurkat (Fig. 5A and data not shown). 
Surface expression of CD40-L by Jurkat was shown by 
immunofluorescence using CD40-Fc (Fig. 5B). 
We studied CD40-L mRNA synthesis in PBMNC 
using the human cRNA probe. CD40-L mRNA was 
detected in unstimulated PBMNC (Fig. 6B). To exclude 
the possibility that this synthesis was a result of in vitro 
stimulation, RNA was isolated immediately after 
PBMNC isolation. CD40-L mRNA could clearly be 
detected in RNA from freshly isolated PBMNC (Fig. 
6C). CD40-L mRNA is strongly upregulated by stimu- 
lation with ionomycin plus PMA (Fig. 6A), with a max- 
imum steady state level at about 3 hours. Binding of 
FITC-la~lled CD40-Fc paralleled the mRNA level and 
261 
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Fig. 2. Nucleotide and predicted amino acid sequence of the cDNA 
clone 6. The two potential N-glycosylation sites are boxed. The puta- 
tive transmembrane domam is underlined and the five eystemes are 
boxed 
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showed that the expression of the ligand could be in- 
duced in a large fraction of the PBMNC (Fig. 6). To 
determine which immun~om~tent cells could be in- 
duced to express CD40-L mRNA, cel‘i populations pos- 
itive for CD4, CD& CD45R0, CD45RA, CD14 and 
CD20 were isolated from PBMNC by FACS and stim- 
ulated far 6 hours with ionomycin and PMA . RNA was 
tested for the presence of CD40-L mRNA by Northern 
blot. A signal could be detected only in stimulated and 
unstimulated CD4, CD& CD&R0 and CD45RA cells 
{Fig. 7A and data not shawn). Moreover CD8’/CD57- 
and CDX*/CD57’ cells were purified by FACS sorting 
and stimulated for 6 hours with ionomycin and PMA. 
CD40-L mRNA was detected by Northern blot hy- 
bridisation on both activated cell populations (data not 
shown). 
To confirm that both CD40-L mRNA and protein 
could be detected in CDS-positive cells we stimulated 
the CD3’, CD8+, CDlK, clone OZZ 50. 1 with ionomy- 
tin plus PMA. A signal for the CD40-L mRNA could 
clearly be detected (Fig. 7Af. Imm~lno~uores~ence 
using FITC-labelied CD40-Fc indicated that synthesis 
of the mRNA was paralleled by appearance of CD40-L 
at the surface of 20% of the cells (data not shown). 
To show that CD40-L could be detected on the sur- 
face of activated CD4+, CD8’, CD45RO’ and 
CD45RA’ celk, PBMNC activated for 6 hours were 
double Iabelled using different anti-CD mAbs and 
CD40-Fc (Fig. 7B). Binding of CD40-Fc was restricted 
to CD3” cells with less than 1% of CD3- cells expressing 
CD40-L. The majority of the CD4* cells (79%) ex- 
pressed the CD40-L as judged by CD40-Fc binding 
(Fig. 7). CD40-L could be detected on 41% of the acti- 
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Fig. 3. Alignment of the primary sequence of human CD4Q-L with murine CM-L, human TNFGc and TNFfi _ Areas of amino acid identity (dark] 
or similarity (shaded) are indicated. 
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Fig. 4. Expression of human CD40-L in BHK ceils transfected with CD40-L cDNA in anti sense (A) or sense orientation (B). Transfected BHK 
cells were analysed for CD40-Fc OF IgG2a binding as indicate in Fig. 1. 
vated CD8’ cells (Fig. 7). We did not observe differ- 
ences between ‘memory’ or ‘virgin’ T cells as expression 
of CD40-L was induced on 72% of both CD45RA+ and 
CD45RO’ cells (Fig. 7B). Under the activation condi- 
tions used, induction of CD40-L synthesis was re- 
A 
rfim 
-CK?m-Llsf&4 
e!zthmRfaA 
*j Jwkat 
Fig, 5. CD40-L mRNA level in nine human cell lines (A) and CD40-L 
protein in Jurkat cells (B). RNA (2 pg aliquots) isolated from unstim- 
ulated cells (-) or cells incubated (f) for 4 h with ionomycin (I PM) 
and PMA (10 nglml) were subjected to Northern blot assay with 
CD40-L cRNA (upper autoradiograph) or actin cDNA flower autora- 
diograph) probes. Auroradiography exposure time: 72 h. Jurkat cells 
were analysed for CD40-Fc or IgG,, binding as indicated in Fig. 1. 
stricted to T cells and could not be detected on B cells 
(< 0.3%), NK cells (< 0.8%) or monocytes (< 1%). 
3.4. Effect of IgE regulatory ~yt~kine~ on~~4~-~~ga~~ 
r&WA level 
Murine CD40-L in conjunction with IL-4 has been 
shown to induce IgE synthesis in purified human B cells 
[lo], We observed that human C!D40-L and its mRNA 
could both be detected in CD4* T cells clones 5 days 
after stimulation with irradiated PBMNC, PHA and 
IL-2 (Fig. 8 and data not shown). Human CD4+ T cell 
clones activated using these conditions are capable of 
inducing, in the presence of IL-4, IgE synthesis by 
human B cells [27,28]. The expression of CD40-L 
mRNA was stable for 9 days in activated T cell clones 
cultured in the presence of IL-4 alone as illustrated for 
the clone JF7 (Fig. 8). This satisfied time required for 
s~tchi~g to the E constant region and IgE synthesis 
[27,28]. These findings indicate that synthesis of the 
CD40-L could be detected under conditions which are 
used to promote IgE synthesis in vitro. 
IgE synthesis can be induced by IL-4 alone in 
PBMNC. We therefore studied if induction of IgE pro- 
duction was paralleled by a change in CD40-L synthe- 
sis. We observed that incubation of PBMNC with IL-4 
more than 6 days reproducibly caused up regulation of 
CD40-L mRNA as illustrated in Fig. 8. I~unofluo~ 
rescence using CD40-Fc was not sensitive enough to 
detect CD40-L after stimulation with IL-4 alone. In 
contrast, the up regulation of CD40-L mRNA was pre- 
vented by the addition of IFNy (Fig. 8). Together these 
findings indicate that CD40-L expression is influenced 
by factors which regulate IgE production. 
263 
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Fig. 6. CD40-L protein and CD40-L mRNA expression in PBMNC 
immediately after isolation (D; Dl and D2 represents two different 
blood donors) or PBMNC cultured for the indicated times in the 
absence or presence of ionomycin (1 ,uM) and PMA (10 @ml). North- 
ern blot and binding assays were performed as described in Figs. 4 and 
1. Autoradiography exposure time: A, 1 h; B, C and D, 20 h. 
4. DISCUSSION 
We report here the molecular cloning of the human 
CD40-ligand cDNA. Human and murine CD40-L share 
a significant protein sequence homology (77.4%) which 
is consistent with the functional cross-reactivity ob- 
served recently by Armitage et al. [lo]. The encoded 
polypeptide of 261 amino acids consists of 13 amino- 
terminal amino acids, followed by a 32-amino acid se- 
quence of hydrophobic residues, which may function as 
a signal/anchor domain. This configuration is typical 
for a type-II transmembrane protein in which the car- 
boxy terminus is extracellular. The human CD40-L dif- 
fers from the murine counterpart in that it contains two 
potential N-glycosylation sites instead of one (one being 
intracellular), five cysteins instead of four and one extra 
amino acid in position 105. The homology of murine 
CD40-L with TNFa and TNFB , which is shared by 
human CD40-L, has led to a predicted trimer structure 
(Peitsch, M.C. and Jongeneel, V.C., personal communi- 
cation). 
Transfection of the human CD40-L cDNA recloned 
in pCDM8 [21] was followed by detectable binding to 
CD40-Fc indicating that the cDNA could encode for a 
functional protein. 
We studied CD40-L mRNA and protein synthesis in 
PBMNC. The CD40-L mRNA could be detected in 
unstimulated cells. Stimulation of PBMNC with iono- 
mycin and PMA is followed by a very strong increase 
in the CD40-L mRNA level, which is detectable at 30 
minutes. This is accompanied by the ability of a major- 
ity of cells to bind CD40-Fc fusion protein as recently 
reported [29]. Studies on PBMNC subpopulations using 
Northern blot assays or double labelling and FACS 
analysis indicated that synthesis of the CD40-L mRNA 
and protein could be induced on a fraction of CD4, 
CD8, CD45RA, CD45RO but not CD20 or CD14 posi- 
tive cells. The expression of the CD40-L mRNA and 
protein observed in CDS’ cells was confirmed using a 
CD8’ T cell clone. This finding is in line with the report 
FACS-SORTED CELLS 1 CELL CLONES 
&II I I 
CD3 CD4 CD8 
CD45RO CD45RA 
PE-anti-CD 
CD20 
Fig. 7. Analysis of CIXO-L mRNA level (A) or CD40-Fc binding (B) 
in PBMNC sub populations and in CD8’ and CD4’ T cell clones. (A) 
PBMNC sub populations were FACS sorted using mAbs directed 
against he indicated markers (see section 2). Cells (106/ml) were incu- 
bated for 4 h in medium alone (-) or in the presence (+) of ionomycm 
(1 ,uM) and PMA (10 @ml). RNA isolated from 8 x lo6 (CD4’). 
3.5 x lo6 (CD8+), 5 x lo6 (CD20’). 6x lo6 (CD14’). 3 x lo6 
(CD45RA’), 2.5 x lo6 (CD45 RO’) cells was subjected to Northern 
blot analysis with CD40-L cRNA or actin cDNA probes. Parallel 
analysis was done with RNA from the indicated cloned T cells. Au- 
toradiography exposure time: CD40-L probe, 2 h; actin probe, 48 h. 
(B): Contour plot display of PBMNC incubated with optimal concen- 
trations of FITC-CD40-Fc and PE-labelled monoclonal antibodies 
directed against he indicated markers. FACS settings and electromc 
compensation were made on single population of labelled cells. 
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Fig. 8. Expression of CD40-L mRNA in cloned CD4’ T cells and PBMNC activated under conditions used to promote IgE synthesis in vitro. Cloned 
JF7 cells were activated for 5 days with PHA (0.2pg/ml), irradiated PBMNC l@/ml and IL-2 50 U/ml), washed and cultured for the times indicated 
with IL-4 alone (200 U/ml). As a control, resting (day 16 after last stimulation) JF7 cells were stimulated with ionomycin (&M) and PMA (10 
&ml). PBMNC were incubated for the times indicated with medium alone, IL-4 (200 U/ml). IL-4 and anti-CD40 mAb (1 &ml) or IL-4 and IFNy 
(500 O/ml). Northern blot assays for CD40-L and actin mRNA were performed as described in Fig. 4. Autoradiography exposure time: 24 h. 
that some CDS+ T cell clones can be used in conjunction 
with IL-4 to trigger IgE synthesis [30]. 
Binding of CD40 by anti-CD40 mAbs or murine 
CD40-L was shown to induce, in the presence of IL-4, 
switching to the E constant region as well as induction 
of IgE synthesis by purified human B cells [6-lo]. In line 
with these observations, anti-CD40 mAbs induce in B 
cells a strong up regulation of the germline E transcript 
synthesis triggered by IL-4 [9,31]. The second signal 
necessary to induce IgE synthesis in purified B cells can 
be given by cloned CD4’ T cells activated for five days 
with PHA, irradiated PBMNC and IL-2 or membranes 
isolated from stimulated T cells [27,28]. These findings 
are in accordance with a current model in which two 
signals are required for IgE production (reviewed in 
[32]). The first signal is given by the soluble cytokine 
IL-4 [33] which induces germline E transcript expression 
[27] but alone is insufficient to trigger secretion of IgE. 
The second signal is provided by a physical interaction 
between activated T and B cells (reviewed in [32]). The 
CD40/CD40-L pair appears therefore to be a candidate 
for mediating signalling between T and B cells, leading 
to IgE synthesis. 
One aim of the present study was to determine 
whether CD40-L was expressed on immunocompetent 
peripheral blood cells and if expression varied under 
conditions known to affect IgE synthesis. Using a 
human CDIO-L cRNA probe, it was possible to detect 
the corresponding mRNA in both unstimulated and 
stimulated CD4’ and CD8’ T cell clones. In CD4” cells, 
the mRNA level is very strongly upregulated shortly 
after stimulation with ionomycin plus PMA. The results 
of screening the AgtlO library made with RNA isolated 
from stimulated CD4” T cells, suggest that this mRNA 
represents a large fraction (OS-l%) of the poly A’ 
RNA. More relevant for the in vitro model used to 
study IgE synthesis, the CD40-L mRNA and the corre- 
sponding protein can clearly be detected five days after 
activation of cloned CD4’ cells with PHA, irradiated 
PBMNC and IL-2. It is stable when IL-2 is replaced by 
IL-4. 
We examined the expression of the CD40-L in 
PBMNC stimulated with IL-4 under conditions which 
trigger IgE synthesis. Interestingly, under such condi- 
tions the CD40-L mRNA level was upregulated. This 
was paralleled by an increase in CD40-Fc binding. This 
upregulation was prevented by IFNy, a cytokine which 
inhibits IL-4-induced IgE production by PBMNC [34]. 
This indicates that it belongs to the category of IL-4- 
induced effects which can be blocked by IFNy. 
Taken together, these results indicate that the synthe- 
sis of CD40-L can be induced by stimulation of various 
T cell subtypes. The expression of both CD40-L mRNA 
and protein is also observed under conditions which are 
used to trigger switching to the E constant region and 
also IgE synthesis. This suggests that the CD40-L pro- 
vides an important signal in the induction of IgE synthe- 
sis in vitro. The possibility that it represent an adhesion- 
type of surface molecules involved in T cell-B cell inter- 
action such as the CD23 / CD21 pair [35] is under 
investigation. 
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